Roche also included RG7827, a 4-1BBxFAP bispecific antibody, on the list of the candidates removed from its phase 1 pipeline. However, a Roche spokesperson clarified that the action relates to the ...

Roche’s PATHWAY test was used in Enhertu’s DESTINY-Breast06 clinical trial, which demonstrated a median progression-free survival of 13.2 months with the antibody-drug conjugate compared to 8. ...

With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in ... Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out in arenas beyond just prescription counts and sales numbers.

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...

Cervical, lung and breast cancers are among the common types for which Roche's products are used for testing. Ventana Medical Systems, the predecessor company to Roche Tissue Diagnostics ...

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibody-based drugs.

Roche has agreed to help Regeneron manufacture its COVID-19 antibody cocktail REGN-COV2, which started late-stage clinical testing a few weeks ago, in a deal that could more than triple supplies ...